GlassScriptPhysician profile
Robert M Henley
NPI 1619373420
$361.79
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $315 · 2022: $46.36.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $60.76 | 2021 | |
| Abbvie INC. | $38.80 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $35.48 | 2021 | |
| Boston Scientific Corporation | $32.73 | 2022 | |
| Abbott Laboratories | $31.42 | 2021 | |
| Ibsa Pharma INC. | $29.00 | 2021 | |
| Almatica Pharma LLC | $26.81 | 2021 | |
| Biotissue Holdings INC. | $24.40 | 2021 | |
| Collegium Pharmaceutical, INC. | $18.49 | 2021 | |
| Genentech USA, INC. | $17.48 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.81 | 2021 | |
| Novo Nordisk INC | $15.70 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.91 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Henley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.